Glaukos Receives Permanent J-Code for Epioxa™

New J-code for Epioxa™, J2789, set to become effective July 1, 2026

Apr. 16, 2026 at 12:42am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the delicate internal structures of the human eye, conceptually representing the medical innovation behind the new J-code for the Epioxa treatment.The new J-code for Epioxa will help make this innovative treatment more accessible to patients suffering from the progressive eye condition of keratoconus.Aliso Viejo Today

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, announced that it has received a permanent J-code, J2789, for its product Epioxa, effective July 1, 2026. This milestone supports the company's market access initiatives to increase access and expand coverage for patients suffering from keratoconus.

Why it matters

The assignment of a product-specific J-code is an important step for Glaukos, as it will help streamline the reimbursement process for Epioxa and make it more accessible to patients with keratoconus, a progressive eye condition that can lead to vision impairment.

The details

Epioxa is a treatment for keratoconus, a progressive eye condition that can lead to vision impairment. The new J-code, J2789, will become effective on July 1, 2026, and will help support Glaukos' efforts to increase access and expand coverage for Epioxa among patients suffering from keratoconus.

  • The new J-code, J2789, will become effective on July 1, 2026.

The players

Glaukos Corporation

An ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Got photos? Submit your photos here. ›

The takeaway

The new J-code for Epioxa will help streamline the reimbursement process and make the treatment more accessible to patients with keratoconus, a progressive eye condition that can lead to vision impairment.